Tanvex BioPharma, Inc. is a holding company. The Company and its subsidiaries are engaged in the research and development of biosimilar products, biological production processes, and the contract development and manufacturing of biological medicines. It excels in areas such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales, and distribution. Its product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), and Perjeta (TX-52). The Company has two subsidiaries, namely Tanvex Biologies Corporation (Tanvex Taiwan) and Tanvex BioPharma USA, Inc. (Tanvex USA). Tanvex Taiwan is responsible for initial stage cell line development and bioprocess development, while Tanvex USA is responsible for further cell line and process development, scaling up the process to achieve commercialization and mass production.